CorMedix’s ReSPECTful Quarter: CRMD Lifts Guidance as Q1 Revenue Rises and Phase III Momentum Gathers

CRMD • Q1 2026 earnings release • Nasdaq: CRMD

Lede: A Quarter That Sets the Stage for 2027

In Parsippany, New Jersey, CorMedix Therapeutics (Nasdaq: CRMD) reported a solid start to 2026 that looks less like a one-off and more like a deliberate repositioning. The EPS figures land at 0.48 (basic) and 0.43 (diluted) per share for the quarter, with earnings surprise analyses left to the analysts (the company does not publish an EPS consensus in the release). Net income comes in at $38.6 million, and adjusted EBITDA hits $70.0 million, underscoring a quarter powered by a meaningful contribution from the DefenCath portfolio and the recently acquired Melinta lineup. On the revenue front, the revenue forecast for 2026 is raised to a range of $325–$345 million, signaling management’s confidence in a higher run rate.

Financial Highlights

Net revenue for Q1 2026: $127.4 million
Net income for Q1 2026: $38.6 million
Adjusted EBITDA for Q1 2026: $70.0 million
EPS (basic): $0.48 per share; EPS (diluted): $0.43 per share
Revenue drivers: DefenCath contributed $97.5 million in net revenue; the Melinta portfolio added $29.9 million

Pipeline Highlights and Guidance

The company emphasizes progress in late-stage development while maintaining a clear dialogue with regulators:

REZZAYO (rezafungin for injection) — Phase III topline results released on April 27, 2026, for prophylaxis of invasive fungal diseases in adult allogeneic hematopoietic stem cell transplant patients. CorMedix is actively coordinating with its global partner to prepare an sNDA submission to the FDA in the second half of 2026, with a potential commercial launch targeted for 2027.
Taurolidine/Heparin catheter lock solution — Phase III study in TPN patients continues to enroll; management is taking steps to accelerate enrollment, including new study sites and a protocol amendment to broaden eligibility. If approved, this could meaningfully extend the company’s addressable market beyond antifungal prophylaxis.

The 2026 guidance remains intact and is reiterated: net revenue $325–$345 million and adjusted EBITDA $115–$135 million.

Corporate Events and Highlights

The release notes a conference call scheduled for today at 8:30 a.m. Eastern Time. The press materials are consistent about CorMedix’s dual role as a current product revenue engine and a driver of late-stage pipeline development, notably through REZZAYO and the taurolidine/heparin initiatives.

What this Could Portend for CRMD and Its Sector Peers

This quarter reads like a disciplined attempt to turn pipeline risk into optionality. DefenCath’s performance provides ballast—stable, hospital-based revenue that can absorb the volatility that often accompanies a portfolio refresh. The Melinta integration shows up as a tangible uplift in the near term, suggesting the company’s M&A strategy is contributing meaningfully to the top and bottom lines.

The REZZAYO update matters more than a headline suggests. A successful sNDA submission and subsequent 2027 launch would add a new growth vein with a different regulatory and competitive dynamic than the infection-control portfolio. Management’s emphasis on regulatory timing hints at a process where milestones, not quarterly beat metrics, will drive the stock’s narrative for the next 12–24 months.

In terms of sector peers, the quarter reinforces a broader pattern: a diversified product portfolio can provide a floor while the pipeline aims for multiple future payoffs. The acceleration efforts on the taurolidine/heparin program underscore the practical realities of running Phase III trials while maintaining a revenue base from existing products. If the FDA path and eventual commercial launch come to fruition, CRMD could become a more meaningful participant in hospital-based infection control and antifungal prophylaxis.

Risks, Considerations and Near-Term Outlook

Key risks include regulatory timing, the ultimate success of the sNDA for REZZAYO, competition in the antifungal prophylaxis space, and the ability to sustain enrollment momentum in the taurolidine/heparin study. The company’s liquidity posture, ability to manage the integration of Melinta, and execution on the 2026 revenue range will be watched closely by investors who care about EPS trajectory and long-range cash generation.